US Oral Solid Dosage CDMO Market Industry Outlook
According to Rohan Patil, who specializes in oral dosage formulations, CDMO services, and healthcare market intelligence, with 5+ years of experience in market research and industry analysis, extensive research indicates strong growth opportunities in the U.S. oral solid dosage CDMO market. The U.S. oral solid dosage CDMO market size was estimated at USD 14.38 billion in 2025 and is predicted to increase from USD 15.33 billion in 2026 to approximately USD 27.2 billion by 2035, expanding at a CAGR of 6.58% from 2026 to 2035. His analysis highlights growing complex drug formulations, generic drug products, and advanced manufacturing technologies. The research also examines the competitive strategies of key industry participants, including Catalent, Inc., Lonza Group AG, Thermo Fisher Scientific Inc., Piramal Pharma Solutions, Cambrex Corporation, and Recipharm AB, shaping the future of oral solid dosage CDMO in the U.S.
Last Updated : 07 July 2026
Category: Pharmaceuticals
Insight Code: 6996
Format: PDF / PPT / Excel